{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:12:37Z","timestamp":1786626757293,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s40261-018-0626-4","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T02:23:49Z","timestamp":1518747829000},"page":"449-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Antipsychotic Prescribing and Safety Monitoring Practices in Children and Youth: A Population-Based Study in Alberta, Canada"],"prefix":"10.1007","volume":"38","author":[{"given":"Wenxin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Cepoiu-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Stang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Symonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8229-8431","authenticated-orcid":false,"given":"Tamara","family":"Pringsheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,16]]},"reference":[{"key":"626_CR1","unstructured":"Product monograph: Seroquel XR. Astra Zeneca Canada Inc. Available from \n                    https:\/\/www.astrazeneca.ca\/content\/dam\/az-ca\/downloads\/productinformation\/seroquel-xr-product-monograph-en.pdf\n                    \n                  . Revised 2 Mar 2017. Accessed 28 June 2017."},{"key":"626_CR2","unstructured":"Product monograph: Abilify. Otsuka Canada. Available from \n                    http:\/\/otsukacanada.com\/docs\/default-source\/default-document-library\/product-monographs\/abilify_pm_e.pdf?sfvrsn=10\n                    \n                  . Revised 30 Nov 2017. Accessed 28 June 2017."},{"key":"626_CR3","unstructured":"Product monograph: Risperdal. Janssen Inc. Available from \n                    http:\/\/www.janssen.com\/canada\/sites\/www_janssen_com_canada\/files\/prod_files\/live\/risperdal_cpm.pdf.\n                    \n                  . Revised 6 Nov 2014. Accessed 28 June 2017."},{"issue":"4","key":"626_CR4","doi-asserted-by":"publisher","first-page":"E225","DOI":"10.9778\/cmajo.20140009","volume":"2","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim T, Gardner DM. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ Open. 2014;2(4):E225\u201332. \n                    https:\/\/doi.org\/10.9778\/cmajo.20140009\n                    \n                  .","journal-title":"CMAJ Open"},{"issue":"6","key":"626_CR5","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1089\/cap.2010.0145","volume":"21","author":"T Pringsheim","year":"2011","unstructured":"Pringsheim T, Lam D, Patten S. The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009. J Child Adolesc Psychopharmacol. 2011;21(6):536\u201343.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"3","key":"626_CR6","doi-asserted-by":"publisher","first-page":"e010861","DOI":"10.1136\/bmjopen-2015-010861","volume":"6","author":"D Duncan","year":"2016","unstructured":"Duncan D, Cooke L, Symonds C, Gardner D, Pringsheim T. Quetiapine use in adults in the community: a population-based study in Alberta, Canada. BMJ Open. 2016;6(3):e010861. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2015-010861\n                    \n                  .","journal-title":"BMJ Open"},{"issue":"8","key":"626_CR7","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2165\/11592020-000000000-00000","volume":"34","author":"T Pringsheim","year":"2011","unstructured":"Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of second generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf. 2011;34(8):651\u201368.","journal-title":"Drug Saf"},{"issue":"9","key":"626_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/pch\/16.9.581","volume":"16","author":"T Pringsheim","year":"2011","unstructured":"Pringsheim T, Panagiotopoulos C, Davidson J, Ho J. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Pediatr Child Health. 2011;16(9):581\u20139.","journal-title":"Pediatr Child Health."},{"issue":"7","key":"626_CR9","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","volume":"60","author":"L Scahill","year":"2003","unstructured":"Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60(7):1130\u20135.","journal-title":"Neurology."},{"issue":"8","key":"626_CR10","doi-asserted-by":"publisher","first-page":"e772","DOI":"10.4088\/JCP.12m08189","volume":"74","author":"HK Yoo","year":"2013","unstructured":"Yoo HK, Joung YS, Lee JS, Song DH, Lee YS, Kim JW, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette\u2019s disorder. J Clin Psychiatry. 2013;74(8):e772\u201380. \n                    https:\/\/doi.org\/10.4088\/JCP.12m08189\n                    \n                  .","journal-title":"J Clin Psychiatry"},{"key":"626_CR11","doi-asserted-by":"publisher","unstructured":"Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2016; (6). \n                    https:\/\/doi.org\/10.1002\/14651858.cd009043.pub3\n                    \n                  .","DOI":"10.1002\/14651858.cd009043.pub3"},{"key":"626_CR12","doi-asserted-by":"publisher","unstructured":"Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev. 2007; (1). \n                    https:\/\/doi.org\/10.1002\/14651858.cd005040.pub2\n                    \n                  .","DOI":"10.1002\/14651858.cd005040.pub2"},{"issue":"1","key":"626_CR13","doi-asserted-by":"publisher","first-page":"47.e1","DOI":"10.1016\/j.jaac.2013.09.022","volume":"53","author":"MG Aman","year":"2014","unstructured":"Aman MG, Bukstein OG, Gadow KD, Arnold LE, Molina BS, McNamara NK, et al. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit\/hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 2014;53(1):47.e1\u201360.e1. \n                    https:\/\/doi.org\/10.1016\/j.jaac.2013.09.022\n                    \n                   (S0890-8567(13)00785-5 [pii]).","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"issue":"1","key":"626_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/070674371205700109","volume":"57","author":"S Alessi-Severini","year":"2012","unstructured":"Alessi-Severini S, Biscontri R, Collins D, Sareen J, Enns M. Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatry. 2012;57(1):52\u20138.","journal-title":"Can J Psychiatry"},{"issue":"6","key":"626_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/070674371305800608","volume":"58","author":"R Ronsley","year":"2013","unstructured":"Ronsley R, Scott D, Warburton W, Hamdi R, Louie D, Davidson J, et al. A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011. Can J Psychiatry. 2013;58(6):361\u20139.","journal-title":"Can J Psychiatry"},{"issue":"2","key":"626_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/070674371506000204","volume":"60","author":"D Gorman","year":"2015","unstructured":"Gorman D, Gardner D, Murphy A, Feldman M, Belanger S, Steele M, et al. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents wih attention deficit hyperactivity disorder, oppositional defiant disorder or conduct disorder. Can J Psychiat. 2015;60(2):62\u201376.","journal-title":"Can J Psychiat"},{"key":"626_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1176\/appi.ajp.2008.08030383","volume":"166","author":"DW Haupt","year":"2009","unstructured":"Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second generation antipsychotic agents. Am J Psychiatry. 2009;166:345\u201353.","journal-title":"Am J Psychiatry"},{"key":"626_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/archpediatrics.2010.48","volume":"164","author":"E Morrato","year":"2010","unstructured":"Morrato E, Nicol G, Maahs D. Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med. 2010;164:344\u201351.","journal-title":"Arch Pediatr Adolesc Med."},{"issue":"7","key":"626_CR19","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/jamapediatrics.2014.224","volume":"168","author":"T Delate","year":"2014","unstructured":"Delate T, Kauffman YS, Botts SR, Wong C, Gaughan KM. Metabolic monitoring in commercially insured pediatric patients newly initiated to take a second-generation antipsychotic. JAMA Pediatr. 2014;168(7):679\u201381. \n                    https:\/\/doi.org\/10.1001\/jamapediatrics.2014.224\n                    \n                  .","journal-title":"JAMA Pediatr."},{"issue":"5","key":"626_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1177\/070674371205700504","volume":"57","author":"R Ronsley","year":"2012","unstructured":"Ronsley R, Rayter M, Smith D, Davidson J, Panagiotopoulos C. Metabolic monitoring training program implementation in the community setting was associated with improved monitoring in second generation antipsychotic-treated children. Can J Psychiat. 2012;57(5):292\u20139.","journal-title":"Can J Psychiat"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0626-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0626-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0626-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T23:09:13Z","timestamp":1550358553000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0626-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,16]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0626-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,16]]},"assertion":[{"value":"16 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"W. Chen, M. Cepoiu-Martin, A. Stang, D. Duncan, C. Symonds, L. Cooke, and T. Pringsheim have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval for this study was received from the University of Calgary Conjoint Health Research Ethics Board (REB14-0080).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No funding has been received for the conduct of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}